Clinical Trial Update: hCT-MSCs for COVID19 ARDS [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of human umbilical cord tissue-derived mesenchymal stem cells (hCT-MSCs) for COVID-19–related ARDS was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• hCT-MSCs (human cord tissue-derived mesenchymal stem cells)

Snippet

Sponsor: Joanne Kurtzberg, MD | Conditions: COVID, Corona Virus Infection | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-12-20